The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Molinuevo, José Luisca
- dc.contributor.author Gramunt Fombuena, Ninaca
- dc.contributor.author Domingo Gispert, Juanca
- dc.contributor.author Fauria, Karineca
- dc.contributor.author Esteller, Manelca
- dc.contributor.author Minguillón, Carolinaca
- dc.contributor.author Sánchez Benavides, Gonzaloca
- dc.contributor.author Huesa, Gemaca
- dc.contributor.author Morán, Sebastiánca
- dc.contributor.author Dal-Ré, Rafaelca
- dc.contributor.author Camí, Jordi, 1952-ca
- dc.date.accessioned 2017-03-29T10:46:48Z
- dc.date.available 2017-03-29T10:46:48Z
- dc.date.issued 2016
- dc.description.abstract Introduction: The preclinical phase of Alzheimer's disease (AD) is optimal for identifying early pathophysiological events and developing prevention programs, which are shared aims of the ALFA project, including the ALFA registry and parent cohort and the nested ALFA+ cohort study. Methods: The ALFA parent cohort baseline visit included full cognitive evaluation, lifestyle habits questionnaires, DNA extraction, and MRI. The nested ALFA+ study adds wet and imaging biomarkers for deeper phenotyping. Results: A total of 2743 participants aged 45 to 74 years were included in the ALFA parent cohort. We show that this cohort, mostly composed of cognitively normal offspring of AD patients, is enriched for AD genetic risk factors. Discussion: The ALFA project represents a valuable infrastructure that will leverage with different studies and trials to prevent AD. The longitudinal ALFA+ cohort will serve to untangle the natural history of the disease and to model the preclinical stages to develop successful trials.
- dc.format.mimetype application/pdfca
- dc.identifier.citation Molinuevo JL, Gramunt N, Domingo Gispert J, Fauria K, Esteller M, Minguillon C et al. The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease. Alzheimer's & Dementia. 2016;2(2):82-92. DOI: 10.1016/j.trci.2016.02.003
- dc.identifier.doi http://dx.doi.org/10.1016/j.trci.2016.02.003
- dc.identifier.issn 2352-8737
- dc.identifier.uri http://hdl.handle.net/10230/28322
- dc.language.iso eng
- dc.publisher Elsevierca
- dc.relation.ispartof Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2016;2(2):82-92
- dc.rights http://dx.doi.org/10.1016/j.trci.2016.02.003 © 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.keyword Alzheimer's disease
- dc.subject.keyword Dementia
- dc.subject.keyword Cohort studies
- dc.subject.keyword Cognition
- dc.subject.keyword Prevention
- dc.subject.keyword Biomarkers
- dc.subject.keyword Risk factor
- dc.title The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's diseaseca
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion